Literature DB >> 9580856

Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma.

F A Leger1, M Izembart, F Dagousset, L Barritault, G Baillet, A Chevalier, J Clerc.   

Abstract

We performed a prospective random study to assess possible thyroid stunning by a 185-MBq iodine-131 dose used to diagnose thyroid remnants. Patients with differentiated thyroid carcinoma were included after total or near-total thyroidectomy. They were randomly assigned to two groups. In group 0 (G0, 32 patients), iodine-123 administration only was used to diagnose thyroid remnants and/or metastasis, so that no thyroid stunning by 131I would occur. In group 1 (G1, 19 patients), diagnostic imaging was performed with 123I and 185 MBq 131I. 123I imaging was less sensitive than 131I imaging in identifying thyroid remnants in both groups (94%). Thyroid uptake of 123I was measured in both groups (at 2 h) and was not significantly different between the groups. Patients with thyroid remnants who remained in the study (28/32 in G0, 17/19 in G1) were treated with 370 MBq 131I, 5 weeks after treatment (mean time, range 12-84 days). In 12/17 G1 patients thyroid uptake measurement was repeated immediately before treatment. Uptake was equal to 1.97% +/- 0.71% and significantly lower (P < 0.05) than the previous measurement (3.76% +/- 1.50%). Patients were imaged 7 days after administration of the therapeutic dose and the images were compared with the diagnostic images. In 28/28 G0 patients thyroid remnants were unchanged and clearly seen. In 5/17 G1 patients, however the remnants were hardly identified, although they had been clearly seen at the time of diagnosis. We conclude the following: (1) a diagnostic dose of 185 MBq 131I decreases thyroid uptake for several weeks after administration and can impair immediate subsequent 131I therapy; (2) 123I is slightly less sensitive than 131I in identifying thyroid remnants; and (3) the need to scan for thyroid remnants remains to be confirmed, since only 2/51 patients enrolled in this study were not treated with 131I.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9580856     DOI: 10.1007/s002590050223

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  16 in total

1.  Seeking a radiobiological explanation for thyroid stunning.

Authors:  M Medvedec
Journal:  Eur J Nucl Med       Date:  2001-03

2.  Should high hTg levels in the absence of iodine uptake be treated?

Authors:  K E Britton; R R Foley; S L Chew
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-03-04       Impact factor: 9.236

3.  Reply.

Authors:  O Sabri
Journal:  Eur J Nucl Med       Date:  2001-03

Review 4.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

5.  Decreased uptake after fractionated ablative doses of iodine-131.

Authors:  Hurng-Sheng Wu; Huey-Herng Hseu; Wan-Yu Lin; Shyh-Jen Wang; Yao-Chi Liu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-09-04       Impact factor: 9.236

6.  Radioiodine-131 in differentiated thyroid cancer: a retrospective analysis of an uptake-related ablation strategy.

Authors:  Robbert B T Verkooijen; Marcel P M Stokkel; Jan W A Smit; Ernest K J Pauwels
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-01-14       Impact factor: 9.236

7.  Correction for hyperfunctioning radiation-induced stunning (CHRIS) in benign thyroid diseases.

Authors:  C Happel; W T Kranert; D Gröner; B Bockisch; A Sabet; I Vardarli; R Görges; K Herrmann; F Grünwald
Journal:  Endocrine       Date:  2020-03-16       Impact factor: 3.633

8.  A comparison of low versus high radioiodine administered activity in patients with low-risk differentiated thyroid cancer.

Authors:  T Ben Ghachem; I Yeddes; I Meddeb; A Bahloul; A Mhiri; I Slim; M F Ben Slimene
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-05-25       Impact factor: 2.503

9.  Surgical completeness of robotic thyroidectomy: a prospective comparison with conventional open thyroidectomy in papillary thyroid carcinoma patients.

Authors:  Sohee Lee; Cho Rok Lee; Seung Chul Lee; Seulkee Park; Ha Yan Kim; Haiyoung Son; Sang-Wook Kang; Jong Ju Jeong; Kee-Hyun Nam; Woong Youn Chung; Cheong Soo Park; Arthur Cho
Journal:  Surg Endosc       Date:  2013-11-13       Impact factor: 4.584

10.  Thyroid stunning in radioiodine-131 therapy of benign thyroid diseases.

Authors:  Christian Happel; Wolfgang Tilman Kranert; Hanns Ackermann; Ina Binse; Benjamin Bockisch; Daniel Gröner; Ken Herrmann; Frank Grünwald
Journal:  Endocrine       Date:  2018-12-31       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.